Results 141 to 150 of about 15,976 (198)
Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization
Lazaros Konstantinidis +4 more
openalex +2 more sources
Predictive Factors for Macular Atrophy in Patients with Treated Myopic Macular Neovascularization. [PDF]
Ferreira AM +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Video Color OCT Angiography for Myopic Choroidal Neovascularization
Ophthalmology RetinaTo investigate the myopic macular neovascularization (mMNV) features on dynamic video color OCT angiography (OCTA) and the diagnostic rate versus the static, 4-segmentations visualization mode.Retrospective cohort study.Fifty-four patients with mMNV.Sixty-two eyes with high myopia complicated by mMNV were included.
Paolo Milani +9 more
openaire +3 more sources
Ranibizumab for myopic choroidal neovascularization
Expert Opinion on Biological Therapy, 2020Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard-of-care treatment for myopic CNV and ranibizumab has been approved for treating myopic ...
Danny S C, Ng +3 more
openaire +2 more sources

